<DOC>
	<DOCNO>NCT01066429</DOCNO>
	<brief_summary>Poor prognosis dufuse large B-cell lymphoma ( DLBCL ) represent 50 % DLBCL overall cure rate range 50-60 % modern dose-dense immunochemotherapy regimens R-CHOP14 . Using alternative strategy , infusional dose-adjusted R-EPOCH , investigator show 83 % complete response ( CR ) , estimate 5-year overall survival ( OS ) rate 75 % ( García-Suárez et al . British Journal Haematology 2007 , 136:276 ) . Despite improvement outcome , search new treatment strategy continue . Therefore , compare prior R-EPOCH investigator decide investigate whether introduction dexamethasone ( 40 mg IV day 1-5 ) place prednisone ( base upon data demonstrate former associate enhanced Central Nervious System penetration ) reduction treatment interval 3 2 week would feasible might improve outcome group patient .</brief_summary>
	<brief_title>DA-EDOCH14-R Poor-prognosis Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Medication , Dose Method Administration : - Rituximab : 375 mg/m2 , endovenous , accord protocol service , day 1 ( except first cycle , day 5 ) . - Etoposide : 50 mg/m2/day , continuous 24-hour infusion , day 1 4 . - Adriamycin : 10 mg/m2/day , continuous 24-hour infusion , day 1 4 . - Vincristine : 0.4 mg/m2/day , continuous 24-hour infusion , day 1 4 - Dexamethasone : 40 mg , endovenous , day 1 5 . Followed prednisone 30 mg ( day +6 ) , 20 mg ( day +7 ) , 10 mg ( day +8 ) . - Cyclophosphamide : 750 mg/m2 , endovenous , 30 minute , day 5 , end continuous infusion adriamycin , etoposide vincristine . - MESNA ( If dose Cyclophosphamide &gt; 1 g/m2</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Signing Informed Consent . Histology : diffuse large Bcell lymphoma de novo ( primary mediastinal Bcell lymphoma include provided mass great 7 cm large diameter ) follicular NHL grade 3b . aaIPI : 23 . Age : Between 18 70 year . General Condition ( ECOG/WHO ) : Proper organic function , define : FEVI ≥ 40 % , serum creatinine &lt; 150 µmol/L , serum bilirubin &lt; 30 µmol/L , control medical condition : infection , leukocytes ≥ 3.5 x 109/l platelet ≥ 100 x 109/l ( except cause lymphomatous infiltration bone marrow spleen ) . HIVpositive . Pregnancy breastfeed . Serious disease compromise performance therapeutic regimen . Recent history another malignant disease ( except skin cancer different melanoma carcinoma insitu cervix ) , prior radiotherapy chemotherapy , history indolent lymphoma . CNS infiltration diagnosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>poor-prognosis diffuse large B-cell lymphoma</keyword>
	<keyword>dose-adjusted</keyword>
	<keyword>R-EDOCH-14</keyword>
	<keyword>rituximab</keyword>
	<keyword>age-adjusted IPI</keyword>
	<keyword>toxicity</keyword>
</DOC>